OncoMatch/Clinical Trials/NCT05048901
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Is NCT05048901 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Cabozantinib and Lanreotide for neuroendocrine tumors,gastroenteropancreatic.
Treatment: Cabozantinib · Lanreotide — This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of small molecule kinase inhibitor or well-differentiated (W-D) G3 GEP-NET who failed to one line of small molecule kinase inhibitor or chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Disease stage
Required: Stage III, IV
Grade: G1G2well-differentiated G3
G1 or G2 NET of GEP origin with locally advanced or metastatic stage ... or W-D G3 NET of GEP origin with locally advanced or metastatic stage
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: small molecule kinase inhibitor
failed to one line or more than one line of small molecular kinase inhibitor (mTOR inhibitor or other targeted kinase inhibitor)
Must have received: chemotherapy
failed to one line or more than one line of chemotherapy or small molecule kinase inhibitor
Cannot have received: cabozantinib (cabozantinib)
Prior use of cabozantinib
Lab requirements
Blood counts
ANC ≥ 1500/µL without G-CSF support; WBC ≥ 2500/µL; platelets ≥ 100,000/µL without transfusion; hemoglobin ≥ 9 g/dL
Kidney function
serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 mL/min
Liver function
ALT, AST, ALP ≤ 3 x ULN; if liver metastasis, AST, ALT ≤ 5 x ULN; ALP ≤ 5 x ULN with documented bone metastases; total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's disease); serum albumin ≥ 2.8 g/dl; moderate to severe hepatic impairment (Child-Pugh B or C) excluded
Cardiac function
QTcF ≤ 500 ms; no NYHA Class 3 or 4 CHF, unstable angina, serious arrhythmias, recent (within 6 months) stroke, MI, or thromboembolic event
Adequate organ and marrow function ... see full laboratory criteria. Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms ... Cardiovascular disorders: Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias. Uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment. Stroke (including TIA), MI, or other ischemic event, or thromboembolic event (e.g., DVT, PE) within 6 months before first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify